Skip to content
Enrolling by invitationPhase 1

PRoMiSS: Psilocybin and the Role of Music in Set and Setting

NCT07180108 · PRoMiSS · Johns Hopkins University

Closed to entry
Status
Not accepting participants
Phase 1
Phase
100
Target enrolment
1
Study sites
1 US states

What it is testing

Summary

The goal of this clinical trial is to understand how personally meaningful, autobiographically salient music compares to standardized playlists when combined with psilocybin in healthy adults ages 21 to 75. The main questions it aims to answer are: Does autobiographically salient music lead to stronger emotional responses to music, greater acute subjective effects, and more lasting improvements in mood, affect, and well-being compared to standardized or ambient playlists? How are brain and body responses - including EEG activity, respiration, heart rate, and skin conductance - influenced by autobiographically salient music under psilocybin? Do brain and body responses to specific music features differ when the music is autobiographically salient compared to non-salient playlists? Researchers will compare five music conditions: three conditions where an 80-minute block of autobiographically salient music is placed at different points in the 6-hour psilocybin session (0-80 minutes, 80-160 minutes, or 240-320 minutes), a standardized Johns Hopkins psilocybin playlist, and an ambient playlist with no autobiographical content. Participants will: * Take a single oral dose of psilocybin (25 mg) during one study session * Listen to one of the five music conditions while reclining in a comfortable setting * Complete questionnaires about emotions, acute, subjective effects, insight, etc. * Undergo EEG and physiological monitoring (respiration, heart rate, skin conductance) during the session * Complete MRI brain scans before the session and 1 week after psilocybin * Return for follow-ups at 1 day, 1 week, and 1 month after psilocybin * At 1 month, complete a qualitative interview and a nondrug EEG music listening session, where the participant's hear either music from the participant's own psilocybin session or music from another participant's session

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Challenging Experiences Questionnaire

    Measured over Immediately at the end of their experimental session

  • Psychological Insight Questionnaire (PIQ)

    Measured over Immediately at end of experimental session

  • Core Flow State Scale (C-FSS)

    Measured over Immediately at end of experimental session

  • Mystical Experiences Questionnaire (MEQ-30)

    Measured over Immediately at end of experimental session

  • Experience of Unity (11D-ASC)

    Measured over Immediately after experimental session

  • Change in EEG oscillatory power across canonical frequency bands (µV²/Hz)

    Measured over During experimental session up to 10 hours

  • Music Ratings: Autobiographical Salience

    Measured over 1-day following experimental session and immediately post 1-month EEG music listening session

  • Spiritual Experience - Altered States of Consciousness (ASC-11D)

    Measured over Immediately after experimental session

  • Blissful State (11D-ASC)

    Measured over Immediately after experimental session

  • Insightfulness (11D-ASC)

    Measured over Immediately after experimental session

  • Disembodiment (11D-ASC)

    Measured over Immediately after experimental session

  • Impaired Cognition & Control (11D ASC)

    Measured over Immediately after experimental session

  • Anxiety (11D-ASC)

    Measured over Immediately after experimental session

  • Complex Imagery (11D-ASC)

    Measured over Immediately after experimental session

  • Elementary Imagery (11D-ASC)

    Measured over Immediately after experimental session

  • Audio-Visual Synesthesia (11D-ASC)

    Measured over Immediately after experimental session

  • Changed Meaning of Percepts (11D-ASC)

    Measured over Immediately after experimental session

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

21 Years to 75 Years
Ages
All
Sex
Accepted
Healthy volunteers
Inclusion Criteria: * • Fluent in English * No hearing impairment * Right-handed * Have a screening weight ≥ 40 kg (88.18 lbs) with BMI ≥16. * Be medically stable as determined by screening for medical problems via a personal interview, a medical history, a physical examination, an electrocardiogram (ECG), and routine medical blood and urinalysis laboratory tests * Agree to consume approximately the same amount of caffeine-containing beverage (e.g., coffee, tea) that he/she consumes on a usual morning, before arriving at the research unit on the mornings of drug session days. If the participant does not routinely consume caffeinated beverages, he/she must agree not to do so on session days. * Agree to refrain from using any psychoactive drugs within 24 hours of each drug administration. The exceptions are caffeine and nicotine, which can be consumed before arriving for drug administration sessions. * Agree not to take any as needed (PRN) medications on the mornings of drug sessions * Agree not to take sildenafil (Viagra®), tadalafil, or similar medications within 72 hours of each drug administration. * Agree not to use any hair conditioner 24-hours before EEG sessions (Visits 3, 4, and 7) * Females of child-bearing potential must agree to use highly effective methods of contraception (defined as use of an intrauterine device, vaginal ring, or implanted or oral hormonal contraceptives) during the study * Agree that for one week before each drug session, he/she will refrain from taking any nonprescription medication, nutritional supplement, or herbal supplement except when approved by the study investigators. Exceptions will be evaluated by the study investigators and will include acetaminophen, non-steroidal anti- inflammatory drugs, and common doses of vitamins and minerals. * Have limited lifetime use of hallucinogens, if any (the following criteria are preferred: no use in the past 5 years; total hallucinogen use less than 10 times) * Proof of COVID-19 vaccination. Exclusion Criteria: * • Unusually low reward response to music (defined as a majority of responses of "1" on the BMRQ) * Women who are pregnant (as indicated by a positive urine pregnancy test assessed at intake and before each drug session) or nursing; women who are of child-bearing potential and sexually active who are not practicing highly effective means of contraception * Cardiovascular conditions: coronary artery disease, stroke, angina, uncontrolled hypertension, a clinically significant ECG abnormality (e.g., atrial fibrillation), prolonged corrected QT interval (QTc) interval (i.e., QTc \> 450 msec), artificial heart valve, or transient ischemic attack (TIA) in the past year * Insulin-dependent diabetes; if taking oral hypoglycemic agent, then no history of hypoglycemia * Currently taking psychoactive prescription medication on a regular (e.g., daily) basis - exceptions may be made at the discretion of the study team physician for participants taking medications with short half-life if participants are able to abstain from taking the medication during session days (e.g. methylphenidate taken for attention or hyperactivity) * Currently taking on a regular (e.g., daily) basis any medications that have a primary centrally-acting serotonergic effect, including Monoamine Oxidase Inhibitors (MAOIs). For individuals who have intermittent or PRN use of such medications, psilocybin sessions will not be conducted until at least 5 half-lives of the agent have elapsed after the last dose. * Current or past history of meeting Diagnostic and Statistical Manual (DSM-5) criteria for schizophrenia spectrum or other psychotic disorders (except substance/medication-induced or due to another medical condition), or Bipolar I Disorder * Current or history within one year of meeting DSM-5 criteria for a moderate or severe substance use disorder. If a nicotine user, consuming the equivalent of more than 10 cigarettes per day. * Have a first-degree relative with schizophrenia spectrum or other psychotic disorders, or bipolar disorder with mania (except substance/medication-induced or due to another medical condition) * Has a psychiatric condition judged to be incompatible with establishment of rapport or safe exposure to psilocybin * History of a medically significant suicide attempt as assessed by a study team clinician * Standard MRI contraindications: head trauma, claustrophobia incompatible with scanning, contraindicated medical devices, prior history as a metal worker and/or certain metallic objects in the body -- must complete MRI screening form and be approved by MRI technologist before each scan * History of migraine. * History of angiotensin-converting enzyme inhibitor (ACEi) angioedema

Where

1 study site

FacilityCityRegionCountry
Center for Psychedelics and Consciousness Research in the Behavioral Biology Research CenterBaltimoreMarylandUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT07180108 on ClinicalTrials.gov →

Last updated in the registry 2025-09-18. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits